Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dianthus Therapeutics ( (DNTH) ) has provided an announcement.
On March 26, 2026, Dianthus Therapeutics posted an updated corporate presentation outlining progress on its autoimmune pipeline and financial position. The company reported pro forma cash of about $1.2 billion, providing runway into 2030 to advance multiple clinical milestones for claseprubart in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, as well as for DNTH212.
In the first quarter of 2026, Dianthus proposed and in March received FDA agreement to streamline safety monitoring across all current and future claseprubart trials. The regulator accepted removal of anti-nuclear antibodies as a screening criterion and routine test, and reclassified the hypothetical systemic lupus erythematosus risk to drug-induced lupus, with the company noting no cases of either condition to date, a shift that could ease trial enrollment and underscore a potentially favorable safety profile.
The most recent analyst rating on (DNTH) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.
Spark’s Take on DNTH Stock
According to Spark, TipRanks’ AI Analyst, DNTH is a Neutral.
Score is held down primarily by worsening losses and accelerating cash burn despite low leverage. Technicals show strong trend strength but are overextended, increasing pullback risk. Offsetting these negatives, major financing and positive Phase 3 progress improve runway and program momentum, while valuation remains constrained by ongoing losses.
To see Spark’s full report on DNTH stock, click here.
More about Dianthus Therapeutics
Dianthus Therapeutics is an autoimmune-focused biopharmaceutical company developing clinical-stage biologics aimed at neuromuscular and other autoimmune diseases. Its lead candidates include claseprubart, a long-acting classical complement pathway C1s inhibitor positioned as a potential best-in-class, first-line biologic, and DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor targeting both innate and adaptive immune pathways in large, underserved markets.
Average Trading Volume: 1,007,691
Technical Sentiment Signal: Buy
Current Market Cap: $3.54B
Find detailed analytics on DNTH stock on TipRanks’ Stock Analysis page.